Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23andMe Holding Co. - Common Stock (NQ:ME)

0.6063 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 23andMe Holding Co. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
From 23andMe, Inc.
Via GlobeNewswire
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population 
From 23andMe, Inc.
Via GlobeNewswire
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
From 23andMe, Inc.
Via GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s 
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025
ME stock results show that 23andMe Holding beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
Via InvestorPlace
23andMe Reports First Quarter Fiscal 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
23andMe stock is up on Friday as investors react to an offer from the company's founder to take it private for 40 cents per share for ME. 
Via InvestorPlace
23andMe Special Committee responds to CEO’s take-private proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer 
From 23andMe, Inc.
Via GlobeNewswire
The 3 Best Personalized Nutrition Stocks to Buy Now
Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
From Kahn Swick & Foti, LLC
Via Business Wire
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks. 
Via InvestorPlace
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
From 23andMe, Inc.
Via GlobeNewswire
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
Business development companies can be a lucrative source of passive income. 
Via The Motley Fool
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
23andMe Launches New Genetic Report on Bipolar Disorder
Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants 
From 23andMe, Inc.
Via GlobeNewswire
Why 23andMe Stock Tumbled 10% on Tuesday
Is altruism a good idea for an unprofitable capitalistic enterprise? 
Via The Motley Fool
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
Study aims to fill research gap and empower people through access to information about their health 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
From 23andMe, Inc.
Via GlobeNewswire
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
Findings from 23andMe research on Parkinson’s disease published in Brain 
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024
ME stock results show that 23andMe Holding beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity 
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q4 and Full Year FY2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.